Raptor Pharmaceutical Corp.'s program to advance RP103 (cysteamine bitartrate delayed-release) in pediatric nonalcoholic steatohepatitis (NASH) "has always been a little bit left of center," president and CEO Julie Anne Smith maintained Monday. "Our core competency is in rare diseases.